Payment overview · 2025
General Payments
$70.66
1 reported records · 1 companies
Healthcare provider profile · identity verified
Richard Alan Smith, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · COLLEGE STATION, TX · NPI 1730270182
Verified facts
What the public records show
CMS Open Payments records show Richard Alan Smith, M.D. received $70.66 in general payments during 2025 across 1 reported records.
AstraZeneca Pharmaceuticals LP accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Symbicort by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $70.66 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $70.66 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $70.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 418 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 414 | 102 |
| Levothyroxine Sodium | Levothyroxine Sodium | 414 | 93 |
| Montelukast Sodium | Montelukast Sodium | 392 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 357 | 101 |
| Simvastatin | Simvastatin | 352 | 95 |
| Metformin Hcl | Metformin Hcl | 332 | 80 |
| Losartan Potassium | Losartan Potassium | 329 | 82 |
| Hydrochlorothiazide | Hydrochlorothiazide | 271 | 60 |
| Jardiance | Empagliflozin | 262 | 41 |
| Gabapentin | Gabapentin | 244 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 242 | 73 |
| Sertraline Hcl | Sertraline Hcl | 227 | 40 |
| Lisinopril | Lisinopril | 213 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 42 |
| Zolpidem Tartrate | Zolpidem Tartrate | 192 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 186 | 45 |
| Alprazolam | Alprazolam | 182 | 51 |
| Furosemide | Furosemide | 177 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 171 | 52 |
| Tramadol Hcl | Tramadol Hcl | 166 | 47 |
| Meloxicam | Meloxicam | 164 | 37 |
| Glimepiride | Glimepiride | 159 | 39 |
| Trazodone Hcl | Trazodone Hcl | 146 | 28 |
| Trulicity | Dulaglutide | 144 | 26 |
| Ozempic | Semaglutide | 132 | 26 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 32 |
| Prednisone | Prednisone | 122 | 71 |
| Bupropion Xl | Bupropion Hcl | 119 | 21 |
| Eliquis | Apixaban | 119 | 18 |
| Potassium Chloride | Potassium Chloride | 114 | 24 |
| Omeprazole | Omeprazole | 111 | 31 |
| Carvedilol | Carvedilol | 103 | 23 |
| Allopurinol | Allopurinol | 102 | 25 |
| Mounjaro | Tirzepatide | 102 | 12 |
| Levofloxacin | Levofloxacin | 101 | 78 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 99 | 50 |
| Mirtazapine | Mirtazapine | 97 | 15 |
| Azithromycin | Azithromycin | 91 | 78 |
| Lorazepam | Lorazepam | 85 | 13 |
| Synthroid | Levothyroxine Sodium | 84 | 24 |
| Oxybutynin Chloride | Oxybutynin Chloride | 81 | 18 |
| Fluconazole | Fluconazole | 80 | 33 |
| Memantine Hcl | Memantine Hcl | 80 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 77 | 17 |
| Alendronate Sodium | Alendronate Sodium | 75 | 16 |
| Celecoxib | Celecoxib | 74 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 74 | 13 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 17 |
| Estradiol | Estradiol | 67 | 15 |
| Pregabalin | Pregabalin | 64 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 61 | 18 |
| Duloxetine Hcl | Duloxetine Hcl | 61 | 14 |
| Glipizide | Glipizide | 61 | 14 |
| Nebivolol Hcl | Nebivolol Hcl | 61 | 19 |
| Atenolol | Atenolol | 59 | 17 |
| Ezetimibe | Ezetimibe | 59 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 58 | 13 |
| Cephalexin | Cephalexin | 58 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 58 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 58 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 57 | 16 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 54 | 13 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 43 |
| Nifedipine Er | Nifedipine | 53 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 52 | 11 |
| Colestipol Hcl | Colestipol Hcl | 50 | 15 |
| Solifenacin Succinate | Solifenacin Succinate | 50 | suppressed |
| Hydrocortisone | Hydrocortisone | 48 | 23 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 48 | 14 |
| Methylprednisolone | Methylprednisolone | 48 | 40 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 47 | 18 |
| Eszopiclone | Eszopiclone | 47 | 11 |
| Buspirone Hcl | Buspirone Hcl | 45 | 11 |
| Febuxostat | Febuxostat | 45 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 42 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 42 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 37 |
| Meclizine Hcl | Meclizine Hcl | 39 | 13 |
| Clonazepam | Clonazepam | 37 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 36 | suppressed |
| Metronidazole | Metronidazole | 36 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 35 | 24 |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Lovastatin | Lovastatin | 31 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 30 | suppressed |
| Finasteride | Finasteride | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 30 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 30 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 27 | suppressed |
| Acyclovir | Acyclovir | 26 | 12 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 25 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Armour Thyroid | Thyroid,pork | 24 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 24 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 24 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 23 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 23 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 21 | suppressed |
| Topiramate | Topiramate | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Baclofen | Baclofen | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 19 | 19 |
| Rybelsus | Semaglutide | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 17 | suppressed |
| Diazepam | Diazepam | 17 | suppressed |
| Prolia | Denosumab | 17 | 11 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Repatha Sureclick | Evolocumab | 16 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Vascepa | Icosapent Ethyl | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Etodolac | Etodolac | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Temazepam | Temazepam | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 11 | suppressed |
| Carisoprodol | Carisoprodol | 11 | suppressed |
| Cefdinir | Cefdinir | 11 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 11 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $70.66 · 1 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error